MK-3222
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for MK-3222, covering 2018-06-13 to 2022-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) [Phase 3]